

Info Sheet for Technical description

No. 0021

Organization

* Mandatory fields

Name of Organization*	Celaid Therapeutics Inc.		
Address, City, States, Zip, Country*	Utokyo Entrepreneur Lab., South Clinical Research Bldg., 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8485, Japan		
URL	https://celaidtx.com/en/about/		
Brief Descriptions of Organization* (Approx. 100 words)	Celaid Therapeutics Inc. is a startup born out of the University of Tokyo and University of Tsukuba with proprietary technology for selective ex vivo HSC expansion. By safely and efficiently expanding human HSCs, Celaid aims to provide the next generation of cell and gene therapy products for cell therapy targeting hematologic disease, ex vivo HSC gene therapy for genetic disorders, and angiogenesis for ischemic diseases.		
Contact address	Name*	Yusuke Inoue	
	Department* / Position	Board Director, COO/CFO	
	E-mail* / TEL	yusuke.inoue@celaidtx.com	

What kind of technology do you want to offer? *

- ☒ **A.** Clinical Development Pipelines → Please see **Sheet [A]**
- ☐ **B.** Regenerative Medicine-related Consumables / Instruments / Materials / CDMO Services etc. → Please see **Sheet [B]**
- ☒ **C.** Platform Technologies(*) that are not included in the above (Group B) → Please see **Sheet [C]**
- * Peripheral technologies that contribute to a significant improvement in productivity throughout the value chain of pharmaceuticals, from research and development to manufacturing and ultimately market launch.

If you agree to the following, please check "Yes" below. *

The technologies introduced in this 'Info Sheet' are in the public domain, as they have been published in research papers or have related patent applications.

☒ Yes

Do you have any collaborations/partnerships with pharmaceutical companies?

☒ Yes

☐ No

If you have already received funding from VCs or other sources, up to which stage has the investment round progressed?

- ☐ Angel / Seed (including AMED/JST grants)
- ☒ Series A
- ☐ Series B
- ☐ Series C
- ☐ Series D or further advanced stages

Do you agree to leave your presentation materials at FIRM hands and entrust us to make use of them for the purpose of promoting your partnering opportunities? *

Options*	Comments
☐ Yes	Please let us know if someone has an interest in our technology.
☒ No	bdcontact@celaidtx.com

Filled in by*

Date*

Celaid Therapeutics Inc.
22-Jul-25

Sheet [A] Clinical Development Pipelines**Info Sheet for Technical overview**

No. A-0021-1

* Mandatoty fields

Title***CLD-001, an ex vivo expanded Hematopoietic Stem Cell (HSC) Therapy****Development Phase***

- | | | |
|---|--|---|
| ☐ Basic Research | ☐ Drug Discovery | ☒ Pre-Clinical |
| ☐ Clinical Trial (Phase I) | ☐ Clinical Trial (Phase II) | ☐ Clinical Trial (Phase III) |
| ☐ Review | ☐ Others | |

Diesease Area*

- | | | |
|--|---|--|
| ☐ Cancer | ☐ Central nervous system | ☐ Ophthalmology |
| ☐ Musculoskeletal | ☐ Endocrine / Metabolism | ☐ Cardiovascular |
| ☐ Urogenital | ☐ Digestive organ | ☒ Blood |
| ☐ Infection | ☐ Dermatology | ☒ Immunity |
| ☐ Otolaryngology | ☐ Respiratory | ☐ Others |

Description*

CLD-001 is being developed as a hematopoietic stem cell therapy product for severe pediatric non-malignant disease. Rare blood diseases such as aplastic anemia, primary immunodeficiency, inherited metabolic disorder, and sickle cell disease, which start in childhood and are associated with various physical and neurological complications, have a very poor prognosis. Currently, the only curative therapy is allogeneic hematopoietic stem cell transplantation (HSCT). On the other hand, there are still significant unmet needs for allogeneic HSCT due to donor problems such as bone marrow donor shortage and HLA type mismatch, as well as side effects such as transplant-related mortality and graft-versus-host disease (GvHD).

CLD-001 is a hematopoietic stem cell product that solves the donor problem, side effects, and disadvantages described above.

In addition to solving the donor problem by using frozen cord blood stored in a cord blood bank as the cell source, CLD-001 also solves the bottleneck of low HSC counts in cord blood with our proprietary HSC expansion technology, enabling us to provide HSCs with the best HLA type for the patient. CLD-001, the HLA best-match and bone marrow-constructible HSCs, is expected to significantly improve overall survival after HSC therapy.

Filled in by***Date***

Celaid Therapeutics Inc.

2025/7/22